Syros Pharmaceuticals (NASDAQ:SYRS) Rating Increased to Hold at StockNews.com

Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday. Syros Pharmaceuticals Price Performance NASDAQ SYRS opened at $5.35 on Thursday. The stock has a market capitalization of $112.72 million, a P/E ratio […]

Leave a Reply

Your email address will not be published.

Previous post TC Bancshares (TCBC) vs. Its Competitors Financial Survey
Next post Baytex Energy Corp. (TSE:BTE) Receives C$6.65 Consensus Price Target from Brokerages